Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Potential effect of the stimulus threshold level of the nociceptive flexion reflex (NFRT) on mortality and delirium incidence in the critically ill patient: a retrospective cohort analysis].

Die Anaesthesiologie·2022

Same author

Development of a PET/EPRI combined imaging system for assessing tumor hypoxia.

Journal of instrumentation : an IOP and SISSA journal·2021

Same author

Articulating a Patient-Centered Design Space for Cancer Journeys.

EAI endorsed transactions on pervasive health and technology·2019

Same author

Mesenchymal stem cells in peripheral blood of severely injured patients.

European journal of trauma and emergency surgery : official publication of the European Trauma Society·2017

Same author

Complement C5a-Induced Changes in Neutrophil Morphology During Inflammation.

Scandinavian journal of immunology·2017

Same author

Evaluation of [Formula: see text] enrichment values obtained with an oral breath test under conditions of impaired gastric functioning.

Journal of breath research·2017

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

A Case of Autoimmune Hepatitis Treated with Rituximab.

E Barth¹, J Clawson

¹United States Air Force, Lackland AFB, San Antonio, Tex., USA.

Case Reports in Gastroenterology

|December 15, 2010

Summary

This summary is machine-generated.

Autoimmune hepatitis (AIH) treatment can be challenging. Rituximab shows promise for AIH patients unresponsive to standard therapies, improving both lab results and liver histology.

More Related Videos

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

Related Experiment Videos

Last Updated: Jun 6, 2026

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

Area of Science:

Hepatology
Immunology
Oncology

Background:

Autoimmune hepatitis (AIH) is a chronic liver disease of unknown cause, historically treated with corticosteroids and azathioprine.
Standard AIH therapies can lead to treatment failures and significant toxicities.
Emerging research explores novel treatments for autoimmune disorders, including rituximab.

Observation:

A case study involved a 34-year-old Caucasian woman with concurrent B cell lymphoma and AIH.
The patient experienced disease progression and steroid toxicity despite initial treatment.
Rituximab was administered for eight weeks to manage the AIH.

Findings:

The patient presented with classic serological and histological features of AIH.
Rituximab treatment led to notable improvements in laboratory markers of liver inflammation.
Histological examination post-treatment indicated a positive response to rituximab.

Implications:

Rituximab may represent a viable therapeutic option for AIH patients with refractory disease or intolerance to conventional treatments.
This case highlights the potential of B-cell targeted therapy in managing complex autoimmune liver conditions.
Further research is warranted to establish the efficacy and safety of rituximab in larger AIH cohorts.